 Melanoma is the most aggressive form of skin cancer, caused by a mutated gene called BRAF-V600. This gene causes uncontrolled growth of melanoma cells, which can spread quickly throughout the body. Patients who have this mutation often respond well to targeted therapies such as BRFI, but eventually become resistant to it. To overcome this resistance, doctors can reintroduce the drug or switch to another targeted therapy. Additionally, pre-clinical studies show that the resistance mechanism of cancer cells to BRAFI therapy is reversible, allowing for the possibility of successful treatment even when the initial therapy fails. This article was authored by Christopher Oses Cosmetes, Konstantina Papadopoulou, Chrissy Maria Mistakadou and others.